This pharma has benefited from massive institutional buying as of late. From a charting perspective it looks to have broken out and successfully retested the trendline breakout. Go long from here
Commentaire:
21st May 2020 - nice retest of the broken trendline and heading higher. 12% return so far
Commentaire:
26th May 2020 - a 28% return on this trade so far